Nadine E Graven, MD
Obstetrics/Gynecology · Escondido
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Graven’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$19,557
Medicare paid this office $19,557 for 45 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 19 | $3,055 | $109 |
| Short return visit (20+ min) | 20 | $2,636 | $75 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,610 | $107 |
Who their Medicare patients are
45 Original Medicare patients in 2024. Average age 73 · Women 100% · Also on Medicaid 29% · Health risk score 1.08. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 64% · Depression 33% · Diabetes 27%.
The office billed $69,979, Medicare allowed $25,288 and paid $19,557; for 143 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 45 | 143 | 73 | 1.08 | $69,979 | $19,557 |
| 2023 | 56 | 173 | 71 | 0.79 | $38,647 | $16,377 |
| 2022 | 16 | 36 | 71 | 0.87 | $5,871 | $2,390 |
| 2017 | 125 | 358 | 68 | 0.67 | $104,290 | $25,544 |
| 2016 | 118 | 366 | 68 | 0.65 | $70,208 | $25,902 |
| 2015 | 73 | 213 | 69 | 0.69 | $32,868 | $13,441 |
| 2014 | 68 | 196 | 69 | 0.65 | $61,470 | $16,116 |
| 2013 | 21 | 49 | 65 | 0.59 | $6,095 | $3,930 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Short return visit (20+ min) | 29 | $3,936 | $76 |
| Return visit (30+ min) | 21 | $2,827 | $101 |
| New patient visit (30+ min) | 16 | $1,403 | $88 |
2017: 7 services
| Return visit (30+ min) | 76 | $7,437 | $79 |
| Short return visit (20+ min) | 56 | $4,419 | $52 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 51 | $2,073 | $41 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 13 | $2,036 | $102 |
| Long return visit (40+ min) | 11 | $1,037 | $94 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $590 | $49 |
| Insertion of needle into vein for collection of blood sample | 13 | $59 | $3 |
2016: 6 services
| Return visit (30+ min) | 90 | $10,403 | $79 |
| Short return visit (20+ min) | 38 | $3,323 | $60 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 63 | $2,659 | $42 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 44 | $2,268 | $52 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 11 | $1,275 | $106 |
| Insertion of needle into vein for collection of blood sample | 11 | $44 | $3 |
2015: 4 services
| Return visit (30+ min) | 35 | $3,590 | $78 |
| Short return visit (20+ min) | 32 | $2,467 | $51 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 27 | $1,399 | $52 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 31 | $1,315 | $42 |
2014: 5 services
| Return visit (30+ min) | 39 | $3,787 | $81 |
| New patient visit (45+ min) | 18 | $2,433 | $135 |
| Short return visit (20+ min) | 21 | $1,812 | $62 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 26 | $1,349 | $52 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 30 | $1,280 | $43 |
2013: 1 service
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 11 | $472 | $43 |
Medicaid work
$5,670 in 2024
Medicaid paid $5,670 for 56 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 43 | $3,884 |
| Return visit (30+ min) | 13 | $1,786 |
| 2024 | 56 | 2 | 15 | $5,670 |
| 2023 | 152 | 4 | 24 | $15,113 |
| 2022 | 24 | 2 | 12 | $2,563 |
| 2021 | 14 | 1 | 13 | $0 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 100 | $8,673 |
| Ultrasound by transvaginal approach | 26 | $3,153 |
| Return visit (30+ min) | 12 | $1,667 |
| New patient visit (30+ min) | 14 | $1,620 |
2022
| New patient visit (30+ min) | 12 | $1,484 |
| Short return visit (20+ min) | 12 | $1,079 |
2021
| Medication list documented in medical record (COA) | 14 | $0 |
Drugs they prescribed that Part D paid
$35,615
Pharmacies billed $35,615 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 376) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
280 generic and 96 brand-name prescriptions · $35,615 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 23 | $12,771 | $555 |
| Estradiol (Twice Weekly) | 59 | $6,213 | $105 |
| Estradiol | 109 | $5,594 | $51 |
| Imvexxy | 18 | $4,765 | $265 |
| Progesterone | 58 | $1,396 | $24 |
See all 9 drugs
| Myrbetriq | 23 | $12,771 | $555 |
| Estradiol (Twice Weekly) | 59 | $6,213 | $105 |
| Estradiol | 109 | $5,594 | $51 |
| Imvexxy | 18 | $4,765 | $265 |
| Progesterone | 58 | $1,396 | $24 |
| Tolterodine Tartrate Er | 18 | $1,013 | $56 |
| Medroxyprogesterone Acetate | 18 | $206 | $11 |
| Fluconazole | 11 | $72 | $7 |
| Levothyroxine | 17 | $62 | $4 |
Year by year
| 2024 | 376 | 87 | 0% (0) | 26% | $35,615 |
| 2023 | 251 | 70 | 0% (0) | None | $23,594 |
| 2022 | 49 | 21 | 0% (0) | 39% | $4,032 |
| 2021 | 31 | None | 0% (0) | None | $522 |
| 2020 | 22 | None | 0% (0) | None | $3,265 |
| 2019 | 73 | None | 0% (0) | 25% | $5,145 |
| 2018 | 204 | 48 | 0% (0) | 36% | $25,231 |
| 2017 | 636 | 95 | None | 29% | $50,718 |
| 2016 | 702 | 89 | None | None | $48,284 |
| 2015 | 543 | 66 | None | None | $35,123 |
| 2014 | 266 | 52 | None | 30% | $17,996 |
| 2013 | 121 | 27 | 0% (0) | None | $9,095 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Myrbetriq | 14 | $7,758 | $554 |
| Estradiol | 77 | $4,883 | $63 |
| Estradiol (Twice Weekly) | 46 | $4,563 | $99 |
| Tolterodine Tartrate Er | 18 | $1,977 | $110 |
| Progesterone | 28 | $1,060 | $38 |
2022: 1 drug
| Estradiol (Twice Weekly) | 14 | $851 | $61 |
2019: 1 drug
| Estradiol | 16 | $167 | $10 |
2018: 3 drugs
| Premarin | 11 | $5,133 | $467 |
| Estradiol | 50 | $2,251 | $45 |
| Progesterone | 22 | $1,622 | $74 |
2017: 16 drugs
| Myrbetriq | 15 | $7,899 | $527 |
| Premarin | 22 | $7,246 | $329 |
| Estradiol | 161 | $5,769 | $36 |
| Divigel | 12 | $2,784 | $232 |
| Vivelle-Dot | 16 | $2,671 | $167 |
| Minivelle | 14 | $2,491 | $178 |
| Progesterone | 37 | $2,336 | $63 |
| Ibandronate | 20 | $1,870 | $93 |
| Synthroid | 14 | $578 | $41 |
| Levothyroxine | 17 | $281 | $17 |
| Medroxyprogesterone Acetate | 25 | $242 | $10 |
| Phenazopyridine | 11 | $226 | $21 |
| Fluconazole | 14 | $140 | $10 |
| Fluoxetine | 12 | $129 | $11 |
| Hydrochlorothiazide | 14 | $107 | $8 |
| Cephalexin | 12 | $57 | $5 |
2016: 15 drugs
| Estradiol | 184 | $5,681 | $31 |
| Premarin | 18 | $5,449 | $303 |
| Vivelle-Dot | 24 | $3,242 | $135 |
| Progesterone | 77 | $3,217 | $42 |
| Divigel | 12 | $2,602 | $217 |
| Vagifem | 13 | $2,529 | $195 |
| Ibandronate | 11 | $772 | $70 |
| Synthroid | 17 | $566 | $33 |
| Fenofibrate | 12 | $459 | $38 |
| Levothyroxine | 23 | $439 | $19 |
| Atorvastatin | 20 | $366 | $18 |
| Medroxyprogesterone Acetate | 29 | $243 | $8 |
| Escitalopram | 13 | $171 | $13 |
| Fluconazole | 17 | $89 | $5 |
| Alendronate | 14 | $84 | $6 |
2015: 13 drugs
| Vivelle-Dot | 45 | $5,533 | $123 |
| Estradiol | 103 | $3,028 | $29 |
| Progesterone | 42 | $2,442 | $58 |
| Divigel | 11 | $2,228 | $203 |
| Minivelle | 12 | $1,659 | $138 |
| Synthroid | 13 | $404 | $31 |
| Losartan | 17 | $312 | $18 |
| Atorvastatin | 20 | $287 | $14 |
| Cryselle | 13 | $262 | $20 |
| Medroxyprogesterone Acetate | 33 | $230 | $7 |
| Nadolol | 11 | $195 | $18 |
| Fluconazole | 15 | $132 | $9 |
| Atenolol | 12 | $48 | $4 |
2014: 6 drugs
| Vivelle-Dot | 31 | $3,394 | $109 |
| Estrace | 11 | $1,834 | $167 |
| Progesterone | 23 | $1,561 | $68 |
| Medroxyprogesterone Acetate | 21 | $150 | $7 |
| Alendronate | 14 | $100 | $7 |
| Estradiol | 11 | $87 | $8 |
2013: 2 drugs
| Bupropion Xl | 11 | $447 | $41 |
| Alendronate | 14 | $141 | $10 |
Money from drug and device companies
$528 in 2025
| 2025 | 8 | 15 | None | $528 |
| 2024 | 9 | 33 | None | $488 |
| 2023 | 9 | 13 | None | $262 |
| 2022 | 2 | 2 | None | $36 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mayne Pharma Commercial | Bijuva | $318 | 7 payments
|
| Biogen | Zurzuvae | $47 | 2 payments
|
| Shield Therapeutics | Accrufer | $46 | 1 payment
|
| Boston Scientific | Axonics | $30 | 1 payment
|
| Hologic Sales and Service | Aptima | $24 | 1 payment
|
| Organon | Nexplanon | $22 | 1 payment
|
See all 15 published payments
| Mayne Pharma Commercial | Meals · 2025-12-15 | None | $25 |
| Mayne Pharma Commercial | Meals · 2025-11-05 | Bijuva | $123 |
| Mayne Pharma Commercial | Meals · 2025-10-28 | Annovera | $120 |
| Mayne Pharma Commercial | Meals · 2025-09-30 | None | $13 |
| Mayne Pharma Commercial | Meals · 2025-07-02 | None | $12 |
| Mayne Pharma Commercial | Meals · 2025-06-13 | None | $14 |
| Boston Scientific | Meals · 2025-06-11 | Axonics | $30 |
| Organon | Meals · 2025-06-09 | Nexplanon | $22 |
| Biogen | Meals · 2025-04-15 | Zurzuvae | $20 |
| Shield Therapeutics | Meals · 2025-04-11 | Accrufer | $46 |
| Mayne Pharma Commercial | Meals · 2025-04-10 | None | $10 |
| Millicent US | Meals · 2025-03-31 | Femring | $19 |
| Hologic Sales and Service | Meals · 2025-03-25 | Aptima | $24 |
| Biogen | Meals · 2025-03-19 | Zurzuvae | $28 |
| Evofem Biosciences | Meals · 2025-03-05 | Phexxi | $22 |
See earlier years (2024, 2023, 2022)
2024: $488
| Daiichi Sankyo | Injectafer | $142 | 15 payments
|
| Astellas Pharma US | Veozah | $136 | 7 payments
|
| Biogen | Zurzuvae | $50 | 2 payments
|
| Pfizer | Premarin | $43 | 3 payments
|
| Aspira Women's Health | Ova1 | $35 | 2 payments
|
| Hologic Sales and Service | Aptima | $23 | 1 payment
|
| Evofem Biosciences | None | $21 | 1 payment
|
| Exeltis USA | Slynd | $19 | 1 payment
|
| Minerva Surgical | None | $19 | 1 payment
|
2023: $262
| Aspira Women's Health | Ova1 | $61 | 3 payments
|
| Mayne Pharma Commercial | None | $44 | 2 payments
|
| CooperSurgical | Paragard T 380a | $38 | 2 payments
|
| Ethicon US | Stratafix | $26 | 1 payment
|
| Becton Dickinson and | Bd Onclarity | $24 | 1 payment
|
| Abbvie | Lo Loestrin Fe | $23 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $19 | 1 payment
|
| Pfizer | Comirnaty | $15 | 1 payment
|
| Daiichi Sankyo | Injectafer | $13 | 1 payment
|
2022: $36
| Hologic | Aptima | $19 | 1 payment
|
| Mayne Pharma | None | $17 | 1 payment
|
Professional record
- NPI
- 1295899847
- Licence
- CA G079068
- Trained
- University of Missouri, Columbia School of Medicine, 1986
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- Po Box 321299, Los Gatos, CA, 95032
- NPI first listed
- 2006-12-20
- NPI last updated
- 2012-04-09
This is when the NPI record was last certified, not a medical board exam.